Difference between revisions of "Mesonephric adenocarcinoma"

From Libre Pathology
Jump to navigation Jump to search
(split out)
Tag: Removed redirect
 
(2 intermediate revisions by the same user not shown)
Line 13: Line 13:
*[[Mesonephric duct remnants]].
*[[Mesonephric duct remnants]].
*[[Cervical adenocarcinoma]].
*[[Cervical adenocarcinoma]].
**[[Clear cell carcinoma of the uterine cervix]].
*[[Colorectal adenocarcinoma]].
*[[Colorectal adenocarcinoma]].
*Endometrioid adenocarcinoma.
*[[Endometrioid endometrial adenocarcinoma]].
*[[Clear cell adenocarcinoma of the uterus]].


==IHC==
==IHC==
Line 39: Line 39:


[[Category:Diagnosis]]
[[Category:Diagnosis]]
[[Category:Gynecologic pathology]]

Latest revision as of 19:17, 17 November 2021

Mesonephric adenocarcinoma is a rare malignant tumour of the uterine cervix.

General

Microscopic

Features:[1]

  • Nuclear atypia - key feature.
    • Nuclear crowding.
  • Variable architecture:
    • Tubular, papillary, solid, retiform (net-like[2]).

DDx:

IHC

Features:[1]

  • CK7 +ve.
  • CD10 +ve.
  • AMACR +ve.
  • Napsin A +ve.[3]
  • HNF-1beta +ve/-ve.
    • Not useful for differentiation from clear cell carcinoma of the gynecologic tract.[3]

Others:[1]

  • CK20 -ve.
  • ER -ve.
  • PR -ve.
  • CEA -ve.

See also

References

  1. 1.0 1.1 1.2 Humphrey, Peter A; Dehner, Louis P; Pfeifer, John D (2008). The Washington Manual of Surgical Pathology (1st ed.). Lippincott Williams & Wilkins. pp. 442. ISBN 978-0781765275.
  2. URL: http://www.thefreedictionary.com/retiform. Accessed on: 25 August 2012.
  3. 3.0 3.1 Pors J, Segura S, Cheng A, Ji JX, Tessier-Cloutier B, Cochrane D, Fix DJ, Park K, Gilks B, Hoang L (September 2020). "Napsin-A and AMACR are Superior to HNF-1β in Distinguishing Between Mesonephric Carcinomas and Clear Cell Carcinomas of the Gynecologic Tract". Appl Immunohistochem Mol Morphol 28 (8): 593–601. doi:10.1097/PAI.0000000000000801. PMC 6987010. PMID 31361605. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6987010/.